Home » Newsletters » BioWorld Science

BioWorld Science

April 6, 2006

View Archived Issues

Preclinical and clinical investigation of SNS-595 in cancer advances

Ambit Biosciences presents new FLT-3 inhibitor for AML

Wyeth presents novel class of selective cPLA2alpha inhibitors for inflammation

IND cleared for phase I study of D93

Orphan drug designation for EPI-A0001

Epix and Predix sign merger agreement

Geron studies GRN-163L in patients with solid tumor malignancies

Phase III breast cancer trial of Tykerb with capecitabine exceeds primary endpoint

Novel 5-HT6 antagonists from Korean Research Institute of Chemical Technology

New orally active progesterone receptor agonists presented by Wyeth

U.S. subsidiaries form new Daiichi Sankyo

Astellas to acquire worldwide rights to Amevive

FDA completes IND review for Oncaspar in NHL and solid tumors

Trials of CX-717 placed on clinical hold

Incyte discontinues development of DFC

Initial preclinical data for ReN-003 retinal stem cell therapy program

Dainippon Sumitomo merges U.S. subsidiaries

Orphan drug designation for lestaurtinib in AML

Veronate fails to meet phase III study endpoints

Celebrex reduces precancerous polyps in high-risk patients

PTC-124 shows pharmacological activity in CF patients with nonsense mutation

Novel antiinfective agents reported in recent patent literature

Novel p38alpha MAPK inhibitors emerge from Pfizer R&D

Novel agents for respiratory disorders disclosed in recent patents

Taclonex now available in U.S.

Pyridopyridazines with potent and selective dual PI3-kinase/ERK2-inhibitory activity

Second approvable letter for Surfaxin

Antitumor activity of RGB-286638, a potent, broad-spectrum CDK inhibitor

Oncogenic B-Raf inhibitor advanced as first oncology candidate at Plexxikon

Antitumor activity of potent multiple-kinase inhibitor further characterized

Novel inhibitors of hepatitis C virus replicon system identified

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...